{"url_path":"/sec/ewtx/8-k/2026-06-05/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-05","source_url":"https://www.sec.gov/Archives/edgar/data/1710072/0001104659-26-071011-index.html","accession_number":"0001104659-26-071011","cik":"0001710072","ticker":"EWTX","issuer_name":"Edgewise Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1710072/0001104659-26-071011-index.html","primary_entity_key":"0001710072","primary_entity_name":"Edgewise Therapeutics, Inc."},"word_count":233,"has_tables":true,"body_markdown":"** **\n\n \n\n \n\n \n\n**Item 5.07.**\n**SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.**\n\n \n\nEdgewise Therapeutics, Inc. (the “Company”)\nheld its Annual Meeting of stockholders (the “Annual Meeting”) on June 4, 2026. The matters voted upon at the Annual Meeting\nand the voting results for each proposal are set forth below.\n\n** **\n\n**Proposal 1: Election of three Class II Directors**\n\n** **\n\nName of Director \nFor  \nWithheld \n\nLaura Brege \n 87,300,827  \n3,822,867 \n\nBadreddin Edris, Ph.D. \n 64,082,681  \n27,041,013 \n\nJonathan Root, M.D. \n 59,213,781  \n31,909,913 \n\n \n\nEach director nominee was duly elected to serve until the 2029 annual\nmeeting of stockholders and until their successor is duly elected and qualified, subject to earlier resignation or removal.\n\n \n\n**Proposal 2: Ratification of the Appointment of Independent Registered\nPublic Accounting Firm**\n\n** **\n\nFor  \nAgainst  \nAbstain \n\n99,637,228  \n1,123  \n578,031 \n\n \n\nThe stockholders ratified the appointment of KPMG LLP as the Company’s\nindependent registered public accounting firm for the fiscal year ending December 31, 2026.\n\n \n\n**Proposal 3: Advisory Vote on the Compensation of the Company’s\nNamed Executive Officers**\n\n** **\n\nFor  \nAgainst  \nAbstain \n\n87,055,111  \n3,491,326  \n577,257 \n\n \n\nThe stockholders approved, on an advisory and non-binding basis, the\ncompensation of the Company’s named executive officers.\n\n \n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements of the Securities Exchange Act of 1934,\nthe registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n**EDGEWISE THERAPEUTICS, INC.**\n\n \n \n \n\n \nBy:\n/s/ Kevin Koch\n\n \n \nKevin Koch, Ph.D.\n\n \n \nPresident and Chief Executive Officer\n\n \n\nDate: June 5, 2026"}